ARVN - Arvinas Inc

Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.

52W High

$29.61

52W Low

$5.90

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.39

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

17.70

EV/EBITDA (<8 favorable)

-1.62

EV/Revenue (<3 favorable)

5.69

P/S (TTM) (<3 favorable)

1.54

P/B (<3 favorable)

0.94

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.85%

Institutions (25–75% balanced)

94.20%

Shares Outstanding

73,418,000

Float

62,206,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

372,800,000

Gross Profit (TTM)

392,000,000

EPS (TTM)

-1.01

Profit Margin (>10% good)

-0.20%

Operating Margin (TTM) (higher better)

-3.15%

ROE (TTM) (>15% strong)

-0.12%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.71

Momentum

Bearish momentum

Value

0.1711

0.1904

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025